Updated 3 June 2025:
Page updated following PDCO adoption of opinion on a class waiver on conditions in May 2025.
The requirement to submit a paediatric investigation plan is waived for specific medicines or classes of medicines that:
do not represent a significant therapeutic benefit over existing treatments for paediatric patients.
The Paediatric Committee (PDCO) adopted an opinion on a class waiver on conditions in May 2025, in accordance with the Paediatric Regulation.
This decision contains the updated list of classes of medicines. It supersedes and replaces the previous class waiver decisions.
For more information and guidance, see:
The table below contains the updated waived classes of medicines for the listed conditions. Regulatory submissions are subject to this list from 2 June 2025 onwards.
| Class of medicines | Condition |
|---|---|
| Androgen receptor modulator, of oestrogen receptor modulator, of growth and sex hormone as well as their releasing or inhibiting factors, and of sex hormone-metabolism modulator medicinal products | Breast malignant neoplasms, prostate malignant neoplasms and neuroendocrine malignant neoplasms |
| First-generation taxoid medicinal products | Breast malignant neoplasms, gynaecological epithelial malignant neoplasms, prostate malignant neoplasms, intestinal malignant neoplasms, pancreatic malignant neoplasms, head and neck epithelial malignant neoplasms as well as lung malignant neoplasms |
| Ecteinascidin medicinal products | Gynaecological epithelial malignant neoplasms |
| Her- / epidermal growth factor-receptor antibody medicinal products | Breast malignant neoplasms, intestinal malignant neoplasms and head and neck epithelial malignant neoplasms |
| Thymidylate synthase inhibitor medicinal products | Intestinal malignant neoplasms and lung malignant neoplasms |
| Colchicum alkaloids (colchicine and its derivatives) medicinal products | Primary gout |
| Androgen antagonist medicinal products | Benign prostatic hyperplasia |
| Pyrimidine- and pyrimidine analogue-containing medicinal products | Breast malignant neoplasms, intestinal malignant neoplasms, lung malignant neoplasms, pancreatic malignant neoplasms, head and neck epithelial malignant neoplasms, skin malignant neoplasms and actinic keratosis |
| First- and second-generation platinum-containing medicinal products | Urinary tract malignant neoplasms, head and neck epithelial malignant neoplasms and lung malignant neoplasms |
| Alkylating-methylating medicinal products | Skin malignant neoplasms |
| Ribonucleotide reductase-beta-2 inhibitor medicinal products | Myeloproliferative neoplasms |
| Primarily alkylating medicinal products | Myeloproliferative neoplasms and mature B, T and NK cell neoplasms |
| Photosensitising medicinal products | Head and neck epithelial malignant neoplasms |
| Retinoic X receptor-activating medicinal products | Mature B, T and NK cell neoplasms |
| Immunomodulatory cytokine medicinal products | Neuroendocrine malignant neoplasms, skin malignant neoplasms, myeloproliferative neoplasms and mature B, T and NK cell neoplasms |
| All classes of medicinal products (NEW) | Diagnosis of IgE-mediated allergy |
| Peroxisome proliferator-activated receptor (PPAR)-gamma modulators, including dual and multiple PPAR modulator (e.g., thiazolidinediones, glitazars, triple modulators) medicinal products | Type II diabetes mellitus |
| All classes of medicinal products | Primary and secondary osteoarthrosis |
| All classes of medicinal products | Organic amnestic syndrome (excluding amnestic syndrome caused by alcohol and other psychoactive substances) |
| All classes of medicinal products | Age-related macular degeneration and diabetic macular oedema |
| All classes of medicinal products | Climacteric symptoms associated with decreased oestrogen levels, as occurring at menopause |
| All classes of medicinal products | Alzheimer's disease |
| All classes of medicinal products | Erectile dysfunction |
| All classes of medicinal products | Chronic obstructive pulmonary disease (COPD) (excluding chronic lung diseases associated with long-term airflow limitation, such as asthma, bronchopulmonary dysplasia, primary cilia dyskinesia, obstructive lung disease related to graft-versus-host disease after [bone-marrow] transplantation) |
| All classes of medicinal products | Vulvar intraepithelial neoplasia |
To contact EMA, please see the options listed on below: